重组人血管内皮抑制素联合FOLFOX4方案治疗晚期胃癌

Advanced Gastric Cancer Treated by Endostar Combined with FOLFOX4 Therapeutic Schedule

目的研究重组人血管内皮抑制素联合FOLFOX4方案治疗晚期胃癌的疗效和毒性。方法自2006年7月至2011年3月,32例晚期胃癌患者接受恩度联合FOLFOX4方案(恩度7.5mg/m2 d1～7,草酸铂85mg/m2,静滴2h,d1;醛氢叶酸200mg/m2,d1,d2;5-氟尿嘧啶(5-Fu)400mg/m2,静推,d1,d2;5-Fu 600mg/m2,静滴22h,d1,d2。2周重复,至少4周期。结果 32例中31例可评估疗效:2例获完全缓解(CR),15例获部分缓解(PR),11例获病情稳定(SD),总有效率为54.8%,中位疾病进展时间7.4个月,中位生存期13个月,1年、3年生存率分别为51.6%、16.1%,主要不良反应为中性粒细胞减少(69.7%),恶心、呕吐(56.2%),神经毒性(69.7%),以1～2级为主。结论重组人血管内皮抑制素联合FOLFOX4方案治疗晚期胃癌有效,不良反应可耐受。

Objective To evaluate the efficacy and toxicity of endostar combined with FOLFOX4 in advanced gastric cancer. Methods Between July,2006 and March,2011,32 patients with advanced gastric cancer were received two-weekly endostar combined with FOLFOX4（ Endostar 7.5 mg/m^2 d1-7＋L-OHP 85 mg/m^2 iv. d1＋CF200 mg/ m^2 iv. d1,d2 ＋ 5-Fu 400 mg/m^2 iv. （bolus）d1,2＋5-Fu 600 mg/m^2 iv. d1,d2）at least for weeks. Results We observed 31 assessable patients,2 cases received CR, 15 cases received PR, 11 cases received SD, OR was 54.8%. The PFS was 7.4 months. The median survival period was 13 months. The one,three year survival rate were 51.6% and 16.1%, respectively. The major toxicities were neutropenia（69.7 %}, nausea and vomiting（56.2 %）, peripheral neuropathy（ 69.7 %）, mainly with 1 - 2 levels. Conclusion The therapeutic schedule of endostar combined with FOLFOX4 is effective and well tolerated.